$NBIO SAN DIEGO, CA / ACCESSWIRE / October 7, 2020
Post# of 102250
(Total Views: 201)
Posted On: 10/07/2020 9:17:11 AM
$NBIO SAN DIEGO, CA / ACCESSWIRE / October 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company"
announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company's flagship drug, Pritumumab (PTB), a monoclonal antibody, for the treatment of Brain Cancer.
Effective November 1, 2020, Douglas Karas, a board director of Nascent Biotech for the past four years, joins the Company's core team as Chief Operating Officer and head of Corporate Development and Dr. Ivan Babic, who has been involved with the Company since 2014, joins officially as Consulting Director of Research.
Sean Carrick, CEO of Nascent Biotech, commented, "As the Company moves into its clinical stage, personnel additions are necessary to support the transition of Nascent Biotech into a key player in the oncology arena by matching the caliber and promise of our intellectual property with an experienced, talented, and credible team."
Dr. Ivan Babic received his doctoral degree in biochemistry and cancer biology from the University of Calgary in Alberta, Canada, and his post-doctoral training at UCLA, focusing on the link between oncogenic signaling and reprogramming of cancer cell metabolism. Dr. Babic's research experience includes the Pacific Neuroscience Institute and Research Center and the John Wayne Cancer Institute's Department of Translational Neurosciences and Neurotherapeutics.
Mr. Douglas Karas has extensive operations management, consulting, risk and regulatory compliance, re-engineering, project management, and system development experience that cuts across operations and applications. He previously spent 20 years at Franklin Templeton Investments, serving in multiple roles, including Vice President of Performance Analysis and Investment Risk, Director of Financial Business Processes & Systems, Senior Manager of Financial Operations, Manager of Financial Program Management Office, and Manager of Treasury Accounting Control Compliance. Mr. Karas has also held positions with Transamerica Life Companies and Federated Investors.
announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company's flagship drug, Pritumumab (PTB), a monoclonal antibody, for the treatment of Brain Cancer. Effective November 1, 2020, Douglas Karas, a board director of Nascent Biotech for the past four years, joins the Company's core team as Chief Operating Officer and head of Corporate Development and Dr. Ivan Babic, who has been involved with the Company since 2014, joins officially as Consulting Director of Research.
Sean Carrick, CEO of Nascent Biotech, commented, "As the Company moves into its clinical stage, personnel additions are necessary to support the transition of Nascent Biotech into a key player in the oncology arena by matching the caliber and promise of our intellectual property with an experienced, talented, and credible team."
Dr. Ivan Babic received his doctoral degree in biochemistry and cancer biology from the University of Calgary in Alberta, Canada, and his post-doctoral training at UCLA, focusing on the link between oncogenic signaling and reprogramming of cancer cell metabolism. Dr. Babic's research experience includes the Pacific Neuroscience Institute and Research Center and the John Wayne Cancer Institute's Department of Translational Neurosciences and Neurotherapeutics.
Mr. Douglas Karas has extensive operations management, consulting, risk and regulatory compliance, re-engineering, project management, and system development experience that cuts across operations and applications. He previously spent 20 years at Franklin Templeton Investments, serving in multiple roles, including Vice President of Performance Analysis and Investment Risk, Director of Financial Business Processes & Systems, Senior Manager of Financial Operations, Manager of Financial Program Management Office, and Manager of Treasury Accounting Control Compliance. Mr. Karas has also held positions with Transamerica Life Companies and Federated Investors.
(0)
(0)Scroll down for more posts ▼